Marshall Wace, LLP Paratek Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.51 $73,399 - $110,319	43,952 New	43,952 $82,000
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $453,996 - $591,199	-111,547 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.7 - $7.24 $658,239 - $1.01 Million	-140,051 Reduced 55.66%	111,547 $542,000
Q2 2021 Aug 13, 2021	BUY	$6.81 - $10.93 $1.71 Million - $2.75 Million	251,598 New	251,598 $1.72 Million
Q1 2020 May 15, 2020	SELL	$2.67 - $4.97 $108,193 - $201,394	-40,522 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.93 - $4.5 $118,729 - $182,349	40,522 New	40,522 $163,000
Q1 2018 May 15, 2018	SELL	$12.65 - $18.85 $609,224 - $907,816	-48,160 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$17.45 - $25.6 $72,818 - $106,828	4,173 Added 9.49%	48,160 $862,000
Q3 2017 Nov 13, 2017	BUY	$18.9 - $28.2 $831,354 - $1.24 Million	43,987	43,987 $1.1 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.